Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
imaging (MRI), bone scan, and computed tomography, are often also performed, especially in men presenting with higher risk disease, to check for disease spread. Screening controversy For many reasons, PSA screening remains controversial. Advocates often base their opinions on the European Randomised study of Screening for ProstateCancer (ERSPC), which suggests that screening may reduce the long term risk of prostatecancer-specific mortality by at least 9% (relative reduction). They also note (...) that substantial observational evidence indicates a reduction in advanced disease and reduction in prostatecancer mortality, which they attribute to the introduction of PSA screening. Opponents of PSA screening highlight the indolent natural course of prostatecancer, citing systematic reviews that reported little or no impact of PSA screening on overall and prostatecancer-specific mortality. Opponents also suggest that the harms and burden from overdiagnosis and overtreatment resulting in unnecessary
, prostate biopsy, prostatecancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes. RESULTS: There were approximately 6 million qualifying men with a full year of data. PSA 2018 8. Harms of Prostate -Specific Antigen ( PSA ) screening in prostatecancer : a rapid review Harms of Prostate -Specific Antigen ( PSA ) screening in prostatecancer : a rapid review Harms (...) Prostatecancerscreening Top results for prostatecancerscreening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search
screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 1 Background Prostatecancer is a malignant change in the prostate; as it progresses, it can infiltrate directly adjacent tissue (seminal vesicle, urinary bladder, large intestine) and can form distant metastases. As measured by the number of new cases, prostatecancer is the most common tumourdisease in men in Germany, making up 23.0% of all cancer cases. For 2016, the Robert Koch Institute estimated that about (...) 58 780 men received an initial diagnosis of prostatecancer . Age is considered the most important risk factor for the development of prostatecancer [1, 2]. At a median age of onset of 72 years, prostatecancer occurs predominantly in advanced age; it is rarely found before the 45 th to 50 th year of life . Every year, about 14 000 men in Germany die of the consequences of prostatecancer . The prognosis of the disease decisively depends on the tumour stage as well as tumour typing
has published a white paper to provide some guidance regarding periprocedural prophylaxis. Since prostate biopsies are also an important part of some active surveillance programs, understanding these risks and communicating them to patients is not only integral to informed consent for prostatecancerscreening but also for consideration of treatment options. Once diagnosed with prostatecancer, a man is faced with the risk of overtreatment of indolent disease due to the assumption that diagnosis (...) with a malignancy must necessarily result in treatment of this malignancy. Estimates of overdiagnosis vary widely from less than 5% to more than 75% depending upon the population used with lead times of 5 to 15 years. Although prostatecancer specific mortality and the need for related palliative care is decreased by screening, quality of life may be impaired as a result due to lasting impairment in urinary, bowel, and sexual function. There is considerable distress involved in the decision making process
for prostatecancer using prostate-specific antigen (PSA) testing. STATEMENT OF THE CLINICAL ISSUE Section: Prostatecancer is the second leading cause of cancer deaths among men in the United States, , with the estimated number of deaths exceeding 28,000 in 2012. The rationale for screening asymptomatic men for prostatecancer in the general population is the potential for reducing mortality rates through early detection of the disease. However, much controversy exists between the potential harms (...) that a patient's age and level of comorbidity need to be considered when deciding whether to screen for prostatecancer. – Assessing risk for prostatecancer has been achieved through development of prostatecancer risk calculators. These factor not only PSA but other risk factors and tumor markers for prostatecancer as well. Rather than using a cutoff value, individual probabilities for any and aggressive prostatecancers are calculated, with the decision for biopsy based on patient and physician views
Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs
common types of cancer that affects men. In the United States, the lifetime risk of being diagnosed with prostatecancer is approximately 11%, and the lifetime risk of dying of prostatecancer is 2.5%. Many men with prostatecancer never experience symptoms and, without screening, would never know they have the disease. In autopsy studies of men who died of other causes, more than 20% of men aged 50 to 59 years and more than 33% of men aged 70 to 79 years were found to have prostatecancer. In some (...) . The CAP trial was a cluster-randomized trial of a single invitation to PSA-based screening in the United Kingdom among 415,357 men. Overall, 34% of invited men received a valid PSA screening test. After a median follow-up of 10 years, there was no significant difference in prostatecancer mortality between the invited group and the control group (absolute risk, 0.30 per 1000 person-years vs 0.31 per 1000 person-years, respectively). Based on clinical stage, tumor grade, and PSA level, prostatecancer
PSA screening, prostate biopsy, and treatment of prostatecancer in the years surrounding the USPSTF recommendation against prostatecancerscreening. The 2012 United States Preventive Services Task Force recommendation against screening for prostatecancer has impacted rates of prostate-specific antigen (PSA) screening and appears to be associated with declining prostatecancer incidence. Our objective was to characterize health care utilization that may explain these observed (...) trends.MarketScan claims, which capture >30 million privately insured patients in the United States, were queried for all men aged 40-64 years for the years 2008-2014. PSA testing, prostate biopsy, prostatecancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes.There were approximately 6 million qualifying men with a full year of data. PSA testing, prostate biopsy
malignancy that if left untreated would have had a benign or indolent natural history and would have been of no clinical significance). Randomized trials have therefore been conducted. Randomized trials of PSA screening The Prostate, Lung, Colorectal, and Ovarian (PLCO) CancerScreening Trial The PLCO CancerScreening Trial is a multicenter, randomized, two-armed trial designed to evaluate the effect of screening for prostate, lung, colorectal, and ovarian cancers on disease-specific mortality. From 1993 (...) Antigen (PSA) or Digital Rectal Exam (DRE) The evidence is insufficient to determine whether screening for prostatecancer with prostate-specific antigen (PSA) or digital rectal exam (DRE) reduces mortality from prostatecancer. Screening tests are able to detect prostatecancer at an early stage, but it is not clear whether this earlier detection and consequent earlier treatment leads to any change in the natural history and outcome of the disease. Observational evidence shows a trend toward lower
of Cancer; Humans; Male; Mass Screening /adverse effects; Prostate-Specific Antigen; ProstaticNeoplasms Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32015000712 Date abstract record published 09/06/2015 Health (...) Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms
you like to save your information to view later? Create an account and sign in to keep your Decision box results and view them later. You can also: Continue without an account and print your profile when the process is completed ProstateCancerScreening Men between the ages of 55 and 69 with at least a 10-year life expectancy. Screening is appropriate for people who do not carry a disease that affects their life expectancy. The prostate-specific antigen (PSA) blood test is used to screen men (...) ProstateCancerScreening Boîte à décision | Box details Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your profile and consult your decision boxes. Email
was restricted to studies published in English. The search queries were based on a combination of exploded and non-exploded subject headings and free-text keywords. These terms included prostatecancer, prostaticneoplasms, prostatetumour, prostate-specific antigen (PSA), digital rectal examination (DRE), DRE, mass screening, screening test, early detection of cancer, cancerscreening, screening, PSA, transrectal ultrasound (TRUS), TRUS, ran- domized, false-negative and false-positive; we used alterna- tive (...) . Introduction The goal of prostatecancer (PCa) screening is to reduce the morbidity and mortality from this disease through early detection. There has been a steady decline in PCa mortality following the introduction of PSA testing in the late 1980s. 1 However, phase III trials on PCa screening have demon- strated a high number needed to treat, suggesting many PCas diagnosed were not destined to have an impact on a patient’s overall survival. 2,3 (Level 1 Evidence.) We review the literature on PCa
Personalized risks of overdiagnosis for screen-detected prostatecancer incorporating patient comorbidities: Estimation and communication. Shared patient-physician decision-making regarding treatment for prostatecancer detected by prostate-specific antigen screening involves a complex calculus weighing the risk of the cancer and patient life expectancy. We investigated quantifying these competing risks using the probability that the cancer was "overdiagnosed"-i.e., would not have been (...) clinically diagnosed (diagnosed without screening) during the patient's remaining lifetime.Using an established model of prostatecancerscreening and clinical diagnosis, we simulated screen-detected cases and determined whether modeled clinical diagnosis would occur before non-cancer death, which was based on comorbidity-adjusted population lifetables. Logistic regression models were fitted to the simulated data and used to estimate overdiagnosis probabilities given patient age, PSA level, Gleason sum
Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostatecancerscreening. Our objective was to determine whether multivariate algorithms based on serum total PSA, the free proportion of PSA, age, digital rectal examination and prostate volume can reduce the rate of false-positive PSA results in prostatecancerscreening more effectively than the proportion of free PSA alone at 95% sensitivity (...) . A total of 1,775 consecutive 55- to 67-year-old men with a serum PSA of 4-10 microg/l in the European Randomized Study of Screening for ProstateCancer were included. To predict the presence of cancer, multivariate algorithms were constructed using logistic regression (LR) and a multilayer perceptron neural network with Bayesian regularization (BR-MLP). A prospective setting was simulated by dividing the data set chronologically into one set for training and validation (67%, n = 1,183) and one test
African Americans' Perceptions of Prostate-Specific Antigen ProstateCancerScreening. In 2012, the U.S. Preventive Services Task Force released a hotly debated recommendation against prostate-specific antigen testing for all men. The present research examines African Americans' beliefs about their susceptibility to prostatecancer (PCa) and the effectiveness of prostate-specific antigen testing in the context of the controversy surrounding this recommendation.This study used a qualitative (...) design to examine perceptions regarding susceptibility and screening. Data were collected at a community health center and three predominantly African American churches in North Carolina. Study participants were 46 African American men and women who attended one of four "listening sessions" for pretesting PCa educational materials (average age = 55 years). Listening sessions of 1.5-hour duration were conducted to pretest materials; while presenting the materials, researchers probed beliefs
cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third most common cause of cancer-related deaths. Prostatecancer is a heterogeneous disease with a variable natural history ranging from low-risk tumours (unlikely to threaten men’s quality or length of life) to highly aggressive forms. The etiology of PC is largely unknown and the established risk factors—older age, ethnicity, and family history—explain only a fraction of variation in disease occurrence (...) , with the majority of cancers being low risk and organ PSA-Based Population Screening for ProstateCancer: OHTAC Recommendation. May 2015; pp. 1–5 3 confined. The detection of intermediate-risk tumours was similar in the study groups and, although the detection of high-grade tumours declined with subsequent screening, the progression of PC to metastasis during follow-up did not decline, potentially limiting the effectiveness of screening programs. Overall, although the probability of having a PC detected
of PSA testing in addition to age-specific reference ranges that should be considered when evaluating the results for serum PSA. It discusses the association between elevated serum PSA levels with common prostaticdiseases, such as prostatitis, benign prostatic hyperplasia, and prostatecancer. The guideline notes the harms of screening. The AUA's recommendation to begin baseline testing at age 40 years is not based on data from clinical trials. In addition, the guideline does not specify a threshold (...) will die of prostatecancer (or 5 in 100 for African American men), this means that 97 in 100 men (or 95 in 100 African American men) will die of something else. Finally, although some men may avoid pain and discomfort commonly associated with advanced disease, this must be balanced against the possibility of incontinence, erectile dysfunction, and other side effects that result from certain forms of aggressive treatment. The goal of screening for any disease is to identify an undiagnosed condition
Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Early Detection of Cancers; Male; Mass Screening; Prostate-Specific Antigen; ProstaticNeoplasms Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber (...) Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Tawfik A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostatecancer Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostatecancer Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostatecancer Shteynshlyuger A, Andriole GL Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of screening for prostatecancer using prostate-specific antigen, compared with no screening, using the preliminary results of the European Randomized Study of Screening